(PharmaNewsWire.Com, July 03, 2019 ) According to the latest report by IMARC Group, titled “Hospital Acquired Disease Testing Market and Forecast 2019-2024”, the global hospital acquired disease testing market size reached US$ 876 Million in 2018. A hospital-acquired infection (HAI), also known as a nosocomial infection, is acquired from hospitals or clinical surroundings such as nursing homes and rehabilitation centers. In several cases, HAI can also be traced in the patient’s microbiome when the protective layer of skin comes in contact with possible threats, which cause infection, particularly after surgical operations. The incubation period of these diseases generally varies from 48 hours to 4 days. Some of the commonly occurring infections include pneumonia, urinary tract infections (UTI) and primary bloodstream infections.
Most patients develop HAIs when they are admitted in emergency rooms (ERs) or intensive care units (ICUs) due to the presence of infected patients as well as contaminated linens, air droplets and hospital equipment. In recent years, owing to rapid urbanization, increasing global population, and modernization of healthcare infrastructure, the number of healthcare facilities has grown around the world, which has consequently led to a rise in the instances of HAIs. Moreover, with continuous innovation in the healthcare sector, various technologies have been developed to prevent, diagnose and monitor HAIs like microarrays, solid phase hybridization, polymerase chain reaction (PCR) and real-time location systems (RTLSs). Some of the other growth-inducing factors are inflating morbidity rates, increasing geriatric population, lack of proper hygiene in hospitals and rise in multi-drug resistant organisms (MDROs). Looking forward, the market is projected to reach a value of US$ 2,190 Million by 2024, expanding at a CAGR of around 16.5% during 2019-2024.
Based on the indication, the market has been classified into UTI, surgical site infection (SSI), pneumonia, bloodstream infections, methicillin-resistant staphylococcus aureus (MRSA), and others. Currently, UTI dominates the market, holding the largest share.
Region-wise, the market has been segregated into Europe, Asia Pacific, North America, Latin America, and Middle East and Africa. At present, North America is the biggest market, holding the majority of the global share.
The competitive landscape of the market has also been examined in the report with the detailed profiles of the leading market players. Some of the key players are Abbott Laboratories, Alere, Inc., Becton, Dickinson and Company, bioMérieux SA, F. Hoffmann-La Roche Ltd., Hologic, Inc., QIAGEN, Siemens Healthcare, Diatherix Laboratories, Inc., Meridian Bioscience, Inc., Thermo Fisher Scientific, Inc. (Life Technologies Corporation) and Cepheid, Inc.
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
